|
|
3M-052-AF |
|
Vaxjo ID |
140 |
|
Vaccine Adjuvant Name |
3M-052-AF |
|
Adjuvant VO ID |
VO_0005474
|
|
Description |
A vaccine adjuvant that is a lipid-based nanosuspension of a synthetic TLR7/8 ligand that facilitates adsorption to aluminum oxyhydroxide via the structural properties of the helper lipid employed |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
United States |
|
Host Species for Testing |
Human |
|
Second Host Species for Testing |
Mouse |
|
Components |
3M-052-AF is aqueous nanosuspension of 3M-052 (a synthetic TLR7/8 ligand) and DSPG (i.e., 1,2-distearoyl-sn-glycero-3-phospho-(1′-rac-glycerol)) |
|
Storage |
2-8C |
|
Preparation |
aqueous nanosuspension |
|
Function |
Type: TLR agonist vaccine adjuvant. Target Receptor: Toll-like receptor 7 (TLR7) | Toll-like receptor 8 (TLR8). Induces Th1-biased immune profile. innate immune activation |
| References |
(Soza, 2024): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=69]
Fox et al., 2016: Fox CB, Orr MT, Van Hoeven N, Parker SC, Mikasa TJ, Phan T, Beebe EA, Nana GI, Joshi SW, Tomai MA, Elvecrog J, Fouts TR, Reed SG. Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach. Journal of controlled release : official journal of the Controlled Release Society. 2016; 244(Pt A); 98-9107. [PubMed: 27847326].
|
|
